Literature DB >> 20609956

Dapagliflozin, an SGLT2 inhibitor, for diabetes.

Markolf Hanefeld1, Thomas Forst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20609956     DOI： 10.1016/S0140-6736(10)60749-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.

Authors:  James Xu; Rohan Rajaratnam
Journal:  Cardiovasc Diabetol       Date:  2017-02-02       Impact factor: 9.951

2.  Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Authors:  Christine Clar; James Alexander Gill; Rachel Court; Norman Waugh
Journal:  BMJ Open       Date:  2012-10-18       Impact factor: 2.692

Review 3.  Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.

Authors:  Yanling Wu; Yanping Ding; Yoshimasa Tanaka; Wen Zhang
Journal:  Int J Med Sci       Date:  2014-09-06       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.